AmVac AG |
Investment |
| Biopharmacology: Focuses on the fast-growing vaccine
market; fields: gynaecology, urology and lung diseases |
V+1 |
V+2 |
V+3 |
| Place of residence: Switzerland; Web:
www.amvac.ch |
0,31 % |
3,17 % |
0,24 % |
|
Apeptico GmbH
|
Investment |
| Biotechnology: The business model considerably
accelerates the usually long and cost-intensive process of developing
pharmaceuticals; current projects: development of peptides to treat
pulmonary oedema. |
V+1 |
V+2 |
V+3 |
| Place of residence: Austria, Web:
www.apeptico.com |
|
5,81 % |
|
|
axioGenesis AG
|
Investment |
| Biotechnology: New stem cell technology and drug
development, great benefits in drug development on the human heart cell,
for heart attack etc. |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.axiogenesis.com |
1,33 % |
11,40 % |
2,60 % |
|
BMDsys Production GmbH |
Investment |
| Biomedical technology: Research into and development of
innovative devices for cardiac dysrhythmia; currently the only way to
predict the risk of sudden cardiac death. |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.BMDSys.de |
|
12,43 % |
11,90 % |
|
B.O.T. Aircraft AG |
Investment |
| Vehicle technology: Development and manufacture of light
aircraft including aircraft for the severely handicapped; long-term
contracts with China and with more and more products now through the
final guarantee inspection; demand has already tripled |
V+1 |
V+2 |
V+3 |
| Place of residence: Liechtenstein, Web:
www.bot-aircraft.com |
|
10,34 % |
|
|
Curadis GmbH |
Investment |
| Biotechnology: Treatment concept: ointment to treat
breast cancer; active ingredient aimed at rapidly reducing tumour volume |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany |
|
4,27 % |
6,10 % |
|
ErlaCos GmbH |
Investment |
| Biotechnology: Development of innovative cosmetics;
patented active complex Quadrollol® for the areas of cellulite and skin
tightening with objectively verifiable results; the active agent is sold
to cosmetic companies with their own product lines [Anti-Aging and Anti-Cellulite
Cream] |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany; Web:
www.erlacos.com |
|
|
5,00 % |
|
Euroferm GmbH |
Investment |
| Biotechnology: Biological pest control; considerably
more effective than traditional plant protection and does not leave a
residue |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany; Web:
www.euroferm.de |
|
11,60 % |
5,80 % |
|
4DForce GmbH |
Investment |
| Biomedical technology/software technology: Specialist in
the measurement of brain waves (BCI technology), medically proven
technology in the interactive entertainment industry; boosts
concentration and coordination |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.4dforce.eu |
|
2,50 % |
|
|
Fiagon GmbH |
Investment |
| Biomedical technology: Navigation systems for ENT
surgery; considerable reductions in surgery costs; helps hospitals cover
costs |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.fiagon.de |
|
|
9,90 % |
|
Gerromed GmbH |
Investment |
| Biomedical technology: Leading provider of products and
services for the professional care of patients with chronic wounds |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.gerromed.com |
|
3,85% |
|
|
Govecs GmbH |
Investment |
| Vehicle technology: Manufacturer and distributor of
electric scooters; recommended by the German automobile association, the
ADAC; maintenance and marketing by BOSCH; named best electric scooter of
the year in 2011 |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.govecs.com |
2,66 % |
8,65 % |
|
|
GRIDContent Group
|
Investment |
| IIPTV: Development, manufacture, rental and operation of
television networks and Internet TV |
V+1 |
V+2 |
V+3 |
| Place of residence: Switzerland, Web:
www.grid-tv.com |
|
25,0 % |
|
|
GRID TV Schweiz
|
Investment |
| IPTV: Development, manufacture, rental and operation of
television networks and Internet TV |
V+1 |
V+2 |
V+3 |
| Place of residence: Switzerland, Web,
www.grid-tv.com |
|
25,0 % |
|
|
GRID TV Deutschland
|
Investment |
| IPTV: Development, manufacture, rental and operation of
television networks and Internet TV |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.grid-tv.com |
|
25,0 % |
|
|
Hallufix AG
|
Investment |
| Medical aid: A solution for "hallux valgus" or bunions =
deformation of the big toe, most common in women: splint to correct the
toe position approved for prescription by state doctors; can be worn
with normal shoes; company shoe range |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.hallufix.org |
|
|
2,13 % |
|
Hospita Medical AG
|
Investment |
| Sales and operating company: prevention centres and innovative medical products on behalf of hospitals or doctors, construction of the MFI centre in cooperation with BMDsys under the trademark “Mein Herz Check” (“My heart check”). |
V+1 |
V+2 |
V+3 |
| Place of residence: Switzerland |
|
25 % |
|
|
INDAGO GmbH
|
Investment |
| Biomedical technology: Early diagnosis of bowel cancer
using only blood tests and without a colonoscopy; advanced metabolic
test; early disease diagnosis |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.indago-group.com |
|
3,33 % |
|
|
IXODES AG
|
Investment |
| Biopharmacology: Protection from Lyme disease after tick
bites; cream which can destroy the bacteria within four days of
application; the approval process is currently underway (scheduled
approval 2012) |
V+1 |
V+2 |
V+3 |
| Place of residence: Switzerland |
|
|
1,9 % |
|
MagnaMedics GmbH
|
Investment |
| Biotechnology: Develops ultrafine particles for
diagnostics, supplies major pharmaceutical companies which can then
analyse faster and more cheaply |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.magnamedics.com |
|
|
20,39 % |
|
neuroConn GmbH |
Investment |
| Biomedical technology: New treatment for ADHD, epilepsy,
migraines, sleeping disorders, tinnitus; no pills necessary; patient
control of brain signals using biofeedback |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.neuroconn.de |
|
25,0 % |
|
|
PÄXFood GmbH
|
Investment |
| Food technology: Food production and distribution of
innovative snacks based on research by the Fraunhofer Institute; snack:
keep their shape and colour, fat-free with intense flavour; mass
production launched ahead of schedule |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany; Web:
www.paexfood.de |
|
3,75 % |
|
|
ProLupin GmbH |
Investment |
| Food technology: 100 % vegetable lupin foodstuffs:
"LUPINESSE" ice cream first to be launched; extremely high demand;
capacity tripled |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.prolupin.de |
|
10,0 % |
10,0 % |
|
ProximusDA GmbH |
Investment |
| Software technology: Complete software solutions; target
clients: Intel, Infineon, STM, Nokia and Motorola Partial sale executed
and paid out in 2010 |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany; Web:
www.proximusda.com |
|
9,54 % |
|
|
Redbiotec GmbH
|
Investment |
| Biotechnology: Development of virus simulators enabling
the safer, more rapid and less expensive development of vaccines against
diseases such as influenza and cervical cancer |
V+1 |
V+2 |
V+3 |
| Place of residence: Switzerland, Web:
www.redbiotec.ch |
|
2,40 % |
|
|
Rotortec GmbH
|
Investment |
| Vehicle technology: "Gyrocopter", one and two-seater,
cost: € 45,000 to € 65,000; 175km/h, consumption less than 14l,
ultralight, can be used everywhere and landed on all terrains |
V+1 |
V+2 |
V+3 |
| Place of residence: Germany, Web:
www.rotortec.com |
|
10,00 % |
|
|
ugichem GmbH
|
Investment |
| Biotechnology: Development of new gene silencing agents (so-called ugimers); potential to be used widely for various diseases, such as viral infections, inflammatory diseases and metabolic diseases; first and only supplier at present; licences for individual ugimer agents should be sold to the pharmaceutical company according to internal development up to phase 1. |
V+1 |
V+2 |
V+3 |
| Place of residence: Austria, Web:
www.ugichem.com |
|
|
6,82 % |
